Prise en charge du myélome multiple : Que se passe-t-il après un traitement à base de lénalidomide?
Résumé
Au cours des deux dernières décennies, une myriade de nouvelles stratégies d’association et de nouveaux agents thérapeutiques pour le traitement du myélome multiple (MM) ont été développés. De nouvelles classes de médicaments telles que les inhibiteurs du protéasome, les immunomodulateurs et les anticorps monoclonaux, ont démontré des résultats d’efficacité très prometteurs en ce qui concerne les paramètres de survie et d’amélioration de la qualité de vie des patients atteints de myélome.
Références
Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014 Sep 4;371(10):906-17. doi:10.1056/NEJMoa1402551
Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020 May 11;10(5):53. doi:10.1038/s41408-020-0311-8
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi:10.1056/NEJMoa1611750
O’Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma. Br J Haematol. 2018 Jul;182(2):222-230. doi:10.1111/bjh.15261
Stewart AK, Rajkumar SW, Dimopoulos MA, Masszi T, Spicka I, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52. doi:10.1056/NEJMoa1411321
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi:10.1056/NEJMoa1607751
Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Nov;22(11):1582-1596. doi:10.1016/S1470-2045(21)00466-6
Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. 2017 Sep;31(9):1915-1921. doi:10.1038/leu.2016.380
Brandt J, Shearer B, Morgan SG. Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare. J Pharm Policy Pract. 2018 Nov 7;11:28. doi:10.1186/s40545-018-0154-x
Shustik J, Tay J, Hollmann S, LeBlanc R. A Canadian cost impact analysis comparing maintenance therapy with bortezomib versus lenalidomide in multiple myeloma patients ineligible for stem cell transplant. Value in Health. May 2014;17(3):PA76. doi:10.1016/j.jval.2014.03.446
Cherniawsky HM, Kukreti V, Reece D, Masih-Khan E, McCurdy A, Jimenez-Zepeda VH, et al. The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database. Haematologica. 2021 Jun 1;106(6):1733-1736. doi:10.3324/haematol.2020.259093
Dimopoulos M, Weisel K, Moreau P, Anderson LD, White D, et al. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia. 2021 Jun;35(6):1722-1731. doi:10.1038/s41375-020-01021-3.
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. doi:10.1056/NEJMoa1606038
Spencer A, Lentzch S, Weisel K, Avet-Loiseau H, Mark TM, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018 Dec;103(12):2079-2087. doi:10.3324/haematol.2018.194118
Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020 Jul;34(7):1875-1884. doi:10.1038/s41375-020-0711-6
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jun;20(6):781-794. doi:10.1016/S1470-2045(19)30152-4
Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017 Aug 24;130(8):974-981. doi:10.1182/blood-2017-05-785246
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096-2107. doi:10.1016/S0140-6736(19)32556-5
Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, et al. Apollo: Phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) alone in patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2020;136(Suppl. 1):5–6. doi:10.1182/blood-2020-135874
Mian HS, Eisfeld C, Venner CP, Jimenez-Zepeda V, Khandanpour C, et al. Efficacy of daratumumab containing regimens post lenalidomide maintenance in transplant eligible patients: Real-world experience from the Canadian Myeloma Research Group Database. Blood. 2020;136(Suppl 1):26-27. doi:10.1182/blood-2020-133372
